Literature DB >> 19636332

Impact of treating the metabolic syndrome on chronic kidney disease.

Varun Agrawal1, Aashish Shah, Casey Rice, Barry A Franklin, Peter A McCullough.   

Abstract

The metabolic syndrome is defined by the concurrent presence of at least three metabolic disorders that are associated with an increased risk of cardiovascular disease and diabetes. Results from prospective and cross-sectional studies also point to an association between the metabolic syndrome and chronic kidney disease. Visceral obesity and insulin resistance are two important features of the metabolic syndrome that might explain renal injury. We reviewed the literature to examine whether treatment of the metabolic syndrome can favorably influence renal outcomes. Weight loss, regular exercise, and a low-calorie, low-fat diet are first-line treatments of the metabolic syndrome, yet few data are available to indicate that such lifestyle interventions can prevent or reverse renal damage. Similarly, results from few studies show little or no beneficial effect of blood pressure control, use of statins, fibrates, thiazolidinediones or metformin on renal parameters in patients with metabolic syndrome. The reasons for the lack of trials in this research field are also discussed. This Review identifies the need to improve understanding of the role of metabolic syndrome in chronic kidney disease, define consistent criteria for metabolic syndrome and perform clinical trials that analyze renal outcomes as primary end points.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636332     DOI: 10.1038/nrneph.2009.114

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  90 in total

1.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity).

Authors:  Paul D Thompson; David Buchner; Ileana L Pina; Gary J Balady; Mark A Williams; Bess H Marcus; Kathy Berra; Steven N Blair; Fernando Costa; Barry Franklin; Gerald F Fletcher; Neil F Gordon; Russell R Pate; Beatriz L Rodriguez; Antronette K Yancey; Nanette K Wenger
Journal:  Circulation       Date:  2003-06-24       Impact factor: 29.690

2.  Metabolic syndrome: underrated or underdiagnosed?

Authors:  Kristi Reynolds; Paul Muntner; Vivian Fonseca
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

3.  Association of physical activity and renal function in subjects with and without metabolic syndrome: a review of the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Joseph Finkelstein; Ashish Joshi; Michael K Hise
Journal:  Am J Kidney Dis       Date:  2006-09       Impact factor: 8.860

4.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

5.  The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

Authors:  Trevor J Orchard; Marinella Temprosa; Ronald Goldberg; Steven Haffner; Robert Ratner; Santica Marcovina; Sarah Fowler
Journal:  Ann Intern Med       Date:  2005-04-19       Impact factor: 25.391

6.  Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man.

Authors:  J W Rowe; J B Young; K L Minaker; A L Stevens; J Pallotta; L Landsberg
Journal:  Diabetes       Date:  1981-03       Impact factor: 9.461

Review 7.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.

Authors:  Brent E Wisse
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

8.  Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass.

Authors:  Wayne K Nelson; Scott G Houghton; Dawn S Milliner; John C Lieske; Michael G Sarr
Journal:  Surg Obes Relat Dis       Date:  2005-08-26       Impact factor: 4.734

9.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

10.  Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

Authors:  Luc F Van Gaal; André J Scheen; Aila M Rissanen; Stephan Rössner; Corinne Hanotin; Olivier Ziegler
Journal:  Eur Heart J       Date:  2008-04-15       Impact factor: 29.983

View more
  17 in total

Review 1.  Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP).

Authors:  Peter A McCullough; Susan Steigerwalt; Kirit Tolia; Shu-Cheng Chen; Suying Li; Keith C Norris; Adam Whaley-Connell
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

2.  Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.

Authors:  Phyllis August; Regina M Hardison; Fadi G Hage; Oscar C Marroquin; Janet B McGill; Yves Rosenberg; Michael Steffes; Barry M Wall; Mark Molitch
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

3.  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

Authors:  T M E Davis; R Ting; J D Best; M W Donoghoe; P L Drury; D R Sullivan; A J Jenkins; R L O'Connell; M J Whiting; P P Glasziou; R J Simes; Y A Kesäniemi; V J Gebski; R S Scott; A C Keech
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

4.  Urinary cystatin C as a potential risk marker for cardiovascular disease and chronic kidney disease in patients with obesity and metabolic syndrome.

Authors:  Noriko Satoh-Asahara; Takayoshi Suganami; Takafumi Majima; Kazuhiko Kotani; Yasuhisa Kato; Rika Araki; Kazunori Koyama; Taiichiro Okajima; Makito Tanabe; Mariko Oishi; Akihiro Himeno; Shigeo Kono; Akira Sugawara; Masakazu Hattori; Yoshihiro Ogawa; Akira Shimatsu
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

5.  [The metabolic syndrome and early kidney disease: another link in the chain?].

Authors:  Lilach O Lerman; Amir Lerman
Journal:  Rev Esp Cardiol       Date:  2011-04-08       Impact factor: 4.753

6.  Metabolic Syndrome Severity and Risk of CKD and Worsened GFR: The Jackson Heart Study.

Authors:  Mark D DeBoer; Stephanie L Filipp; Solomon K Musani; Mario Sims; Mark D Okusa; Matthew Gurka
Journal:  Kidney Blood Press Res       Date:  2018-04-06       Impact factor: 2.687

Review 7.  Renal outcomes of bariatric surgery in obese adults with diabetic kidney disease.

Authors:  Bhavana B Rao; Abhik Bhattacharya; Varun Agrawal
Journal:  J Nephrol       Date:  2014-03-19       Impact factor: 3.902

8.  Cardiorenal syndromes: pathophysiology to prevention.

Authors:  Peter A McCullough
Journal:  Int J Nephrol       Date:  2010-12-01

Review 9.  NLRP3 Inflammasome in Metabolic-Associated Kidney Diseases: An Update.

Authors:  Wei Xiong; Xian-Fang Meng; Chun Zhang
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

10.  The impact of a community trial on the pharmacological treatment in the individuals with the metabolic syndrome: findings from the Isfahan Healthy Heart Program, 2001-2007.

Authors:  Mojgan Gharipour; Roya Kelishadi; Alireza Khosravi; Shahin Shirani; Mohsen Masjedi; Nizal Sarrafzadegan
Journal:  Arch Med Sci       Date:  2012-12-19       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.